Casi pharmaceuticals announces receipt of an updated non-binding proposal to acquire entire china business of the company

Beijing, cn / access newswire / april 3, 2025 / casi pharmaceuticals, inc. (nasdaq:casi, "casi"), a cayman incorporated biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products, announced that its special committee of the board of directors (the "special committee") has received an updated preliminary non-binding proposal letter (the "proposal letter"), dated april 2, 2025, from dr. wei-wu he, chairman of the board of directors and ceo of the company, to acquire the entire business operations of the company in china and all license-in, distribution and related rights in asia (excluding japan) related to certain pipeline products of the company, including bi-1206, cid-103 and thiotepa, for an aggregate purchase price of $20.0 million, which shall include assumption of approximately $20.0 million of indebtedness of the company (the "proposed transaction"). the proposal letter updates the preliminary non-binding proposal letter submitted by dr. he to the company on june 21, 2024.
CASI Ratings Summary
CASI Quant Ranking